196 related articles for article (PubMed ID: 25006666)
1. CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.
Tarasewicz E; Hamdan R; Straehla J; Hardy A; Nunez O; Zelivianski S; Dokic D; Jeruss JS
Cancer Biol Ther; 2014 Oct; 15(10):1301-11. PubMed ID: 25006666
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin D-overexpressing breast cancer cells.
Zelivianski S; Cooley A; Kall R; Jeruss JS
Mol Cancer Res; 2010 Oct; 8(10):1375-87. PubMed ID: 20736297
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.
Thomas AL; Lind H; Hong A; Dokic D; Oppat K; Rosenthal E; Guo A; Thomas A; Hamden R; Jeruss JS
Cell Cycle; 2017 Aug; 16(15):1453-1464. PubMed ID: 28678584
[TBL] [Abstract][Full Text] [Related]
5. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
6. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance.
Nestal de Moraes G; Delbue D; Silva KL; Robaina MC; Khongkow P; Gomes AR; Zona S; Crocamo S; Mencalha AL; Magalhães LM; Lam EW; Maia RC
Cell Signal; 2015 Dec; 27(12):2496-505. PubMed ID: 26404623
[TBL] [Abstract][Full Text] [Related]
8. Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines.
Cooley A; Zelivianski S; Jeruss JS
Cell Cycle; 2010 Dec; 9(24):4900-7. PubMed ID: 21150326
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.
Tarasewicz E; Rivas L; Hamdan R; Dokic D; Parimi V; Bernabe BP; Thomas A; Shea LD; Jeruss JS
Cell Cycle; 2014; 13(20):3191-201. PubMed ID: 25485498
[TBL] [Abstract][Full Text] [Related]
10. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.
Grillo M; Bott MJ; Khandke N; McGinnis JP; Miranda M; Meyyappan M; Rosfjord EC; Rabindran SK
Breast Cancer Res Treat; 2006 Jan; 95(2):185-94. PubMed ID: 16319987
[TBL] [Abstract][Full Text] [Related]
11. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
12. Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein.
Yoshida T; Zhang Y; Rivera Rosado LA; Chen J; Khan T; Moon SY; Zhang B
Mol Cancer Ther; 2010 Jun; 9(6):1657-68. PubMed ID: 20515940
[TBL] [Abstract][Full Text] [Related]
13. Cryptotanshinone potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3 activity.
Wang J; Zhang G; Dai C; Gao X; Wu J; Shen L; Chen Z; Liu P
J Int Med Res; 2017 Feb; 45(1):220-230. PubMed ID: 28222632
[TBL] [Abstract][Full Text] [Related]
14. Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells.
Lin Z; Zhang X; Zhao F; Ru S
Toxicol Appl Pharmacol; 2019 Mar; 366():75-82. PubMed ID: 30684532
[TBL] [Abstract][Full Text] [Related]
15. TGFβ/Smad3 regulates proliferation and apoptosis through IRS-1 inhibition in colon cancer cells.
Bailey KL; Agarwal E; Chowdhury S; Luo J; Brattain MG; Black JD; Wang J
PLoS One; 2017; 12(4):e0176096. PubMed ID: 28414818
[TBL] [Abstract][Full Text] [Related]
16. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
Bhowmik T; Gomes A
Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
[TBL] [Abstract][Full Text] [Related]
18. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Yadav V; Burke TF; Huber L; Van Horn RD; Zhang Y; Buchanan SG; Chan EM; Starling JJ; Beckmann RP; Peng SB
Mol Cancer Ther; 2014 Oct; 13(10):2253-63. PubMed ID: 25122067
[TBL] [Abstract][Full Text] [Related]
19. Targeting the AKT/GSK3β/cyclin D1/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy.
Shimura T; Kakuda S; Ochiai Y; Kuwahara Y; Takai Y; Fukumoto M
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):540-8. PubMed ID: 21398050
[TBL] [Abstract][Full Text] [Related]
20. Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
Faversani A; Vaira V; Moro GP; Tosi D; Lopergolo A; Schultz DC; Rivadeneira D; Altieri DC; Bosari S
Breast Cancer Res; 2014 May; 16(3):R55. PubMed ID: 24886669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
